Ascelia Pharma AB (publ) (STO:ACE)
Sweden · Delayed Price · Currency is SEK 4.485
+0.020 (0.45%)
Jul 18, 2025, 5:29 PM CET
Ascelia Pharma AB Company Description
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden.
It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer.
The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden.
Ascelia Pharma AB (publ)
| Country | Sweden |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Magnus Corfitzen |
Contact Details
Address: Hyllie Boulevard 34 Malmö, 215 32 Sweden | |
| Phone | 46 7 35 17 91 18 |
| Website | ascelia.com |
Stock Details
| Ticker Symbol | ACE |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010573113 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Julie Waras Brogren | Deputy Chief Executive Officer and Chief Commercial Officer |
| Magnus O. Corfitzen | Chief Executive Officer |
| Andreas Norlin | Chief Scientific Officer |
| Mikael Widell | Head of IR and Communications |